PDS Biotechnology Corp

PDSB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Operating Activities
Net Income $-50.9M $-38.8M $-28.1M $-12.2M $-6.9M
Depreciation & Amortization
Depreciation $182.9K $100.1K $53.1K $31.2K $4.4K
Amortization
Stock-Based Compensation $6.2M $5.3M $2.9M $1.3M $260.4K
Net Cash from Operating Activities $-40.7M $-32.2M $-21.8M $-9.7M $-8.0M
Investing Activities
Capital Expenditures $188.7K $686.7K $1.3M $884.8K $136.9K
Business Acquisitions
Net Cash from Investing Activities $-188.7K $-686.7K $-1.3M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $22.6M $9.1M $139.5M
Net Change in Cash $-18.3M $-23.8M $116.5M $5.9M $7.7M
Free Cash Flow $-40.9M $-32.9M $-23.1M $-10.6M $-8.2M
← Newer Page 2 of 2 Older →